In a laboratory in Singapore, technicians working for a joint venture between Merck and the Wellcome Trust are preparing to turn raw biological material into finished vaccine doses. The material comes from the International AIDS Vaccine Initiative. The platform comes from Merck's approved Ebola vaccine, Ervebo. The urgency comes from the Democratic Republic of Congo, where a Bundibugyo strain outbreak has now killed close to 1,500 people and shows no sign of slowing. None of the participants in this effort are household names in Britain. Yet the country sits at the centre of nearly everything that makes the response possible, and that position is quietly becoming harder to sustain.

Wellcome is a London-based charity with an endowment in the tens of billions of pounds, one of the largest science funders on earth and a fixture of the UK's claim to global health leadership. Oxford University is running its own Bundibugyo vaccine trial using ChAdOx1, the technology that underpinned the Oxford/AstraZeneca Covid vaccine and that Britain still treats as a signature achievement of its research base. The funding coordinating much of this, through the Coalition for Epidemic Preparedness Innovations, draws heavily on money channelled from the Foreign, Commonwealth and Development Office and the Department of Health and Social Care. This is not a case of Britain watching a foreign crisis from a comfortable distance. It is a case of British science doing exactly what ministers like to say it should do.

The difficulty is that the government has spent the past two years dismantling large parts of the machinery that pays for it. Official development assistance is being cut from 0.5 per cent of gross national income to 0.3 per cent by 2027-28, a reduction the Foreign Secretary confirmed earlier this year and one that will shrink the FCDO's programme spending by around a third compared with last year. The funds are being transferred to the defence sector. International Development Committee members have already warned that fragile and conflict-affected states, the DRC prominent among them, will absorb a disproportionate share of the loss. CEPI's own funding runs partly through this same ODA channel. A body created in significant part on British initiative, and still substantially underwritten by the British state, now competes for a shrinking pool of money that the government itself has decided to shrink further.

There is a temptation to treat this as a foreign aid story with no bearing on the NHS. That temptation should be resisted. The infrastructure behind an Ebola vaccine candidate, the rapid trial capacity at Oxford, the manufacturing partnerships Wellcome can broker, the clinical and regulatory expertise that CEPI depends on, is largely the same infrastructure that underwrites Britain's own pandemic preparedness, its ability to scale vaccine production domestically in an emergency, and its standing as a place where life sciences companies choose to run trials and build manufacturing capacity. When the Vaccines Taskforce model that produced the Oxford/AstraZeneca vaccine gets cited as evidence of British exceptionalism, it is worth asking what happens to that exceptionalism when the funding streams around it are cut year after year while workforce and R&D budgets across the health and science system remain under comparable strain.

None of this diminishes what is being attempted here. A single-dose vaccine candidate moving towards clinical testing within months, in response to a strain with no approved vaccine or treatment, is a genuine achievement, and one in which British institutions are doing serious, credible work. But there is a difference between celebrating that work and assuming it is guaranteed to continue at the same pace and scale. Life sciences leaders have been warning for several years that UK research funding, clinical trial capacity and translational investment are all under pressure, even as the government continues to invoke British science as a source of national prestige.

The lesson from the Bundibugyo response is not that Britain lacks the capability to lead on global health security. It plainly does not. The lesson is that capability of this kind is not self-sustaining. It depends on institutions, funding commitments and political will that can be, and currently are being, quietly reduced, even as ministers continue to describe the United Kingdom as a science superpower. A government that wants to keep pointing to episodes like this one as proof of what British science delivers will eventually have to reconcile that claim with the budget lines it keeps cutting.